{
    "clinical_study": {
        "@rank": "137722", 
        "biospec_descr": {
            "textblock": "One additional blood sample (4 ml)will be collected once a day, separated into Draw an\n      additional ~ 4.0 mL from the subject into a syringe once per every 24 hour period. The study\n      site will indicate where and at what time the sample was taken.  This sample is placed into\n      a sodium heparin tube, labeled with the subject number and sampling time and centrifuged on\n      a refrigerated centrifuge. The gained plasma will be frozen at minus 70 degrees Celsius or\n      less and may be used for potential analysis by the Sponsor, should an analysis of outliers\n      indicate the potential presence of an interferent."
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "The study is to demonstrate the accuracy of the OptiScanner in measuring blood glucose\n      levels in critically ill patients when compared to a reference YSI 2300 STAT Plus and the\n      Gem 3000, the reference standard for Erasme University Hospital."
        }, 
        "brief_title": "OptiScanner Versus Standard Blood Glucose Monitoring", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hyperglycemia", 
        "condition_browse": {
            "mesh_term": "Hyperglycemia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed Informed consent.\n\n          -  Age \u2265 18 years.\n\n          -  Admitted to the ICU of Erasme University Hospital.\n\n          -  Expected ICU stay of \u2265 3 days at the time of enrollment (as judged by the Principle\n             Investigator).\n\n          -  APACHE II score of \u2265 10, within the first 24 hours of ICU admission.\n\n          -  Existing central venous catheter + arterial catheter.\n\n          -  No participation in any other investigational interventional study while enrolled in\n             this study.\n\n          -  Hyperglycemia (BG > 150 mg/dl) at the time of admission.\n\n        Exclusion Criteria:\n\n          -  Pregnancy."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Critically ill patients admitted to the intensive care unit (ICU) of Erasme University\n        Hospital in Brussels, Belgium."
            }
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 31, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01720381", 
            "org_study_id": "2001078"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "monitoring", 
            "blood glucose", 
            "intensive care unit"
        ], 
        "lastchanged_date": "October 28, 2013", 
        "location": {
            "contact": {
                "email": "ddurand@ulb.ac.be", 
                "last_name": "Dominique Durand, BS", 
                "phone": "+32 255 555 44 54"
            }, 
            "facility": {
                "address": {
                    "city": "Brussels", 
                    "country": "Belgium"
                }, 
                "name": "Erasme University Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Jean-Charles Preiser, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Alexander Brasseur, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "David Fagnoul, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_groups": "1", 
        "official_title": "Manual vs. Automated moNitoring Accuracy of GlucosE II (MANAGE II)", 
        "overall_official": {
            "affiliation": "Erasme University Hospital", 
            "last_name": "Jean-Charles Preiser, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Belgium: Federal Agency for Medicinal Products and Health Products", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Percent (%) predicted error is the percent (%) error result of the OptiScanner on central venous blood from the superior cava versus the YSI and the GEM using arterial blood.", 
            "measure": "Glucose Prediction error", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01720381"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The Clarke Error Grid analysis shows the percentage of paired values falling within each zone between the glucose results of the OptiScanner on central venous versus the YSI and the GEM  using arterial blood.", 
            "measure": "Clarke Error Grid analysis", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "source": "OptiScan Biomedical Corporation", 
        "sponsors": {
            "collaborator": {
                "agency": "Erasme University Hospital", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "OptiScan Biomedical Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "October 2013"
    }
}